Octagon Capital Advisors LP Buys Arcus Biosciences Inc, ITeos Therapeutics Inc, Apellis Pharmaceuticals Inc, Sells Curis Inc, IVERIC bio Inc, NGM Biopharmaceuticals Inc

• New Purchases: ITOS, KROS, KDNY, IMVT, OLMA, CMPX,
• Added Positions: RCUS, APLS, BBIO, FDMT, IMAB, STOK, IPSC, ARVN,
• Reduced Positions: OMGA, CTKB, CNTB, VERA, AMAM,
• Sold Out: CRIS, ISEE, NGM, IKNA, PMVP, EWTX, DSGN, TENX,

For the details of Octagon Capital Advisors LP's stock buys and sells, go to https://www.gurufocus.com/guru/octagon+capital+advisors+lp/current-portfolio/portfolio

1. Apellis Pharmaceuticals Inc (APLS) - 2,020,911 shares, 18.59% of the total portfolio. Shares added by 26.63%
2. Arcus Biosciences Inc (RCUS) - 2,095,231 shares, 16.50% of the total portfolio. Shares added by 115.97%
3. I-MAB (IMAB) - 1,049,691 shares, 9.68% of the total portfolio. Shares added by 37.31%
4. 4D Molecular Therapeutics Inc (FDMT) - 1,551,070 shares, 6.62% of the total portfolio. Shares added by 86.59%
5. BridgeBio Pharma Inc (BBIO) - 1,767,486 shares, 5.74% of the total portfolio. Shares added by 210.40%

Octagon Capital Advisors LP initiated holding in ITeos Therapeutics Inc. The purchase prices were between $26.23 and $47.86, with an estimated average price of $33.65. The stock is now traded at around $33.830000. The impact to a portfolio due to this purchase was 4.08%. The holding were 450,776 shares as of 2021-12-31.

Octagon Capital Advisors LP initiated holding in Keros Therapeutics Inc. The purchase prices were between $36.95 and $62.89, with an estimated average price of $50.29. The stock is now traded at around $52.090000. The impact to a portfolio due to this purchase was 3.87%. The holding were 340,214 shares as of 2021-12-31.

Octagon Capital Advisors LP initiated holding in Chinook Therapeutics Inc. The purchase prices were between $10.69 and $16.83, with an estimated average price of $14.32. The stock is now traded at around $13.050000. The impact to a portfolio due to this purchase was 1.59%. The holding were 500,000 shares as of 2021-12-31.

Octagon Capital Advisors LP initiated holding in Immunovant Inc. The purchase prices were between $7.33 and $9.32, with an estimated average price of $8.24. The stock is now traded at around $5.490000. The impact to a portfolio due to this purchase was 0.95%. The holding were 572,862 shares as of 2021-12-31.

Octagon Capital Advisors LP initiated holding in Olema Pharmaceuticals inc. The purchase prices were between $8.75 and $30.71, with an estimated average price of $20.45. The stock is now traded at around $4.500000. The impact to a portfolio due to this purchase was 0.42%. The holding were 231,417 shares as of 2021-12-31.

Octagon Capital Advisors LP initiated holding in Compass Therapeutics Inc. The purchase prices were between $2.88 and $4.08, with an estimated average price of $3.56. The stock is now traded at around $2.400000. The impact to a portfolio due to this purchase was 0.15%. The holding were 240,000 shares as of 2021-12-31.

Octagon Capital Advisors LP added to a holding in Arcus Biosciences Inc by 115.97%. The purchase prices were between $31.38 and $48.47, with an estimated average price of $39.08. The stock is now traded at around $30.490000. The impact to a portfolio due to this purchase was 8.86%. The holding were 2,095,231 shares as of 2021-12-31.

Octagon Capital Advisors LP added to a holding in Apellis Pharmaceuticals Inc by 26.63%. The purchase prices were between $30.74 and $49.16, with an estimated average price of $39.7. The stock is now traded at around $42.730000. The impact to a portfolio due to this purchase was 3.91%. The holding were 2,020,911 shares as of 2021-12-31.

Octagon Capital Advisors LP added to a holding in BridgeBio Pharma Inc by 210.40%. The purchase prices were between $11.38 and $53.41, with an estimated average price of $42.17. The stock is now traded at around $8.080000. The impact to a portfolio due to this purchase was 3.89%. The holding were 1,767,486 shares as of 2021-12-31.

Octagon Capital Advisors LP added to a holding in 4D Molecular Therapeutics Inc by 86.59%. The purchase prices were between $19.56 and $32.94, with an estimated average price of $24.43. The stock is now traded at around $13.970000. The impact to a portfolio due to this purchase was 3.07%. The holding were 1,551,070 shares as of 2021-12-31.

Octagon Capital Advisors LP added to a holding in I-MAB by 37.31%. The purchase prices were between $45.28 and $74.5, with an estimated average price of $59.71. The stock is now traded at around $26.720000. The impact to a portfolio due to this purchase was 2.63%. The holding were 1,049,691 shares as of 2021-12-31.

Octagon Capital Advisors LP added to a holding in Stoke Therapeutics Inc by 164.05%. The purchase prices were between $18.11 and $30.72, with an estimated average price of $23.85. The stock is now traded at around $18.930000. The impact to a portfolio due to this purchase was 2.27%. The holding were 783,769 shares as of 2021-12-31.

Octagon Capital Advisors LP sold out a holding in Curis Inc. The sale prices were between $4.45 and $8.09, with an estimated average price of $5.89.

Octagon Capital Advisors LP sold out a holding in IVERIC bio Inc. The sale prices were between $13.83 and $18.78, with an estimated average price of $16.39.

Octagon Capital Advisors LP sold out a holding in NGM Biopharmaceuticals Inc. The sale prices were between $17.26 and $22.02, with an estimated average price of $19.14.

Octagon Capital Advisors LP sold out a holding in Ikena Oncology Inc. The sale prices were between $10.52 and $16.96, with an estimated average price of $13.55.

Octagon Capital Advisors LP sold out a holding in PMV Pharmaceuticals Inc. The sale prices were between $19.99 and $30.01, with an estimated average price of $24.06.

Octagon Capital Advisors LP sold out a holding in Edgewise Therapeutics Inc. The sale prices were between $14.41 and $22.41, with an estimated average price of $18.02.